Summary: “Through MAPS’ tireless work, MDMA — a psychedelic empathogen discovered in 1912 and made illegal in 1985 — is inches away from obtaining FDA approval to be used in the treatment of PTSD.”
Benzinga reports on the results of MAPS’ Phase 3 trial of MDMA-assisted therapy for PTSD, calling the study’s success “a milestone for the entire psychedelics industry.” Learn more about the implications of the successful trial.
Originally appearing here.
